De Novo Mutation in Non-Tyrosine Kinase Domain of ROS1 as a Potential Predictor of Immune Checkpoint Inhibitors in Melanoma

PURPOSE: Despite the success of targeted therapy in c-ros oncogene 1 (ROS1)-rearranged cancers, especially non-small cell lung cancer (NSCLC), the clinical significance of ROS1 de novo mutation has not yet been understood. We sought to elucidate the predictive effect of ROS1 mutation for immune chec...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Front Oncol
Main Authors: Ma, Si-Cong, Zhu, Hong-Bo, Wang, Jian, Zhang, Yan-Pei, Guo, Xue-Jun, Long, Li-Li, Guo, Ze-Qin, Wu, De-Hua, Dong, Zhong-Yi, Bai, Xue
Format: Artigo
Jezik:Inglês
Izdano: Frontiers Media S.A. 2021
Teme:
Oncology
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC8247586/
https://ncbi.nlm.nih.gov/pubmed/34221982
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2021.666145
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki